

Generics in Indonesia

Industry Report | 2024-12-12 | 38 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$350.00
- Site License (PDF) \$525.00
- Enterprisewide license (PDF) \$700.00

Report description:

Generics in Indonesia

Summary

Generics in Indonesia industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2018-23, and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- A generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and branded generics are included in our market scope. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included. Market value is evaluated at ex-factory prices. Market volume refers to the proportion of the total ethical pharmaceutical market in a country or region that is made up of generic drugs. Thus, it is a measure of the market share held by generics, rather than a direct measure of the total market volume. Regional volumes are calculated as averages of countries that comprise the region where volume data exists.
- The Indonesian generics market recorded revenues of \$4.4 billion in 2023, representing a compound annual growth rate (CAGR) of 8.1% between 2018 and 2023.
- Market consumption volume increased with a CAGR of 1.3% between 2018 and 2023, to reach a total of 75.0% of total pharma volume in 2023.
- The growth in the consumption volume of generics in Indonesia is driven by government initiatives. For instance, the universal healthcare program, Jaminan Kesehatan Nasional (JKN), has significantly increased access to affordable healthcare services. This program, launched in 2014, provides coverage to the entire population, which has led to a growing reliance on cost-effective medications such as generics.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in Indonesia
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Indonesia
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Indonesia generics market with five year forecasts by both value and volume

Reasons to Buy

- What was the size of the Indonesia generics market by value in 2023?
- What will be the size of the Indonesia generics market in 2028?
- What factors are affecting the strength of competition in the Indonesia generics market?
- How has the market performed over the last five years?
- What are the main segments that make up Indonesia's generics market?

Table of Contents:

Table of Contents

- 1 Executive Summary
- 1.1. Market value
- 1.2. Market value forecast
- 1.3. Market volume
- 1.4. Market volume forecast
- 1.5. Geography segmentation
- 1.6. Market rivalry
- 1.7. Competitive landscape
- 2 Market Overview
- 2.1. Market definition
- 2.2. Market analysis
- 3 Market Data
- 3.1. Market value
- 3.2. Market volume
- 4 Market Segmentation
- 4.1. Geography segmentation
- 5 Market Outlook
- 5.1. Market value forecast
- 5.2. Market volume forecast
- 6 Five Forces Analysis
- 6.1. Summary
- 6.2. Buyer power
- 6.3. Supplier power
- 6.4. New entrants
- 6.5. Threat of substitutes
- 6.6. Degree of rivalry

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

7 Competitive Landscape

- 7.1. Who are the leading players?
- 7.2. What are the strengths of the leading players?
- 7.3. Has the government recently implemented any initiatives aimed at boosting the market?
- 8 Company Profiles
- 8.1. PT Kalbe Farma Tbk
- 8.2. PT Sanbe Farma
- 8.3. PT Indofarma Tbk
- 8.4. PT Soho Global Health Tbk
- 9 Macroeconomic Indicators
- 9.1. Country data
- 10 Appendix
- 10.1. Methodology
- 10.2. Industry associations
- 10.3. Related MarketLine research
- 10.4. About MarketLine

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com



☐ - Print this form

To place an Order with Scotts International:

☐ - Complete the relevant blank fields and sign

Generics in Indonesia

Industry Report | 2024-12-12 | 38 pages | MarketLine

Select license	License				Price
	Single user licence (PDF)				\$350.00
	Site License (PDF)			\$525.00	
	Enterprisewide license (PDF)				\$700.00
				VAT	
				Total	
	d at 23% for Polish based companies		companies who are un	able to provide a	valid EU V
Email*	d at 23% for Polish based companies	phone* Last Name*	companies who are un	able to provide a	valid EU V
Email* First Name*	d at 23% for Polish based companies	Phone*	companies who are un	able to provide a	valid EU V
Email* First Name* ob title*	d at 23% for Polish based companies	Phone*		able to provide a	valid EU V
Email* First Name* lob title* Company Name*	d at 23% for Polish based companies	Phone* Last Name*		able to provide a	valid EU V
Email* First Name* Job title* Company Name* Address*	d at 23% for Polish based companies	Phone* Last Name* EU Vat / Tax ID /		able to provide a	valid EU V
** VAT will be added Email* First Name* Job title* Company Name* Address* Zip Code*	d at 23% for Polish based companies	Phone* Last Name* EU Vat / Tax ID / City*		able to provide a	valid EU V

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com